Last reviewed · How we verify

Dasatinib 100 MG — Competitive Intelligence Brief

Dasatinib 100 MG (Dasatinib 100 MG) competitive landscape: 0 comparators, recent regulatory actions, upcoming PDUFA, patent timeline.

marketed Small molecule Live · refreshed every 30 min

Target snapshot

Dasatinib 100 MG (Dasatinib 100 MG) — Cedars-Sinai Medical Center.

Comparator set

Auto-detected by same drug class / molecular target / therapeutic area, ranked by phase + recency. Override with ?vs=slug1,slug2,….

DrugGenericSponsorPhaseClassTargetApproval / PDUFA
Dasatinib 100 MG TARGET Dasatinib 100 MG Cedars-Sinai Medical Center marketed

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape

No sponsor landscape data.

Subscribe to ongoing alerts

Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:

Cite this brief

Drug Landscape (2026). Dasatinib 100 MG — Competitive Intelligence Brief. https://druglandscape.com/ci/dasatinib-100-mg. Accessed 2026-05-16.

Build your own brief

Pick any drug + add comparators: